# NCT06337318 (NCT06337318)

> Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06337318
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Classic Follicular Lymphoma; Follicular Lymphoma With Unusual Cytological Features
- Interventions: Biospecimen Collection; Computed Tomography; Mosunetuzumab; Positron Emission Tomography; Rituximab; Rituximab and Hyaluronidase Human
- Enrollment: 600
- Primary outcome: 3-year milestone progression free survival (PFS)
- Primary outcome: PFS

## Commentary we found

- YouTube: 7
- Podcasts: 3
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06337318

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06337318", "email": "<work email>"}; the inbox owner confirms by the emailed link.